Literature DB >> 25762196

Increased levels of irisin in people with long-standing Type 1 diabetes.

D Espes1,2, J Lau1, P O Carlsson1,2.   

Abstract

BACKGROUND: Irisin stimulates browning of white adipose tissue and improves metabolic control in mice. Betatrophin, another recently described hormone, improves metabolic control in mice by inducing β-cell proliferation. In vitro, irisin stimulates the expression of betatrophin in rat adipocytes. There is a great interest in developing drugs that target or use these hormones for the treatment of obesity and diabetes. We have previously reported on increased levels of betatrophin in people with Type 1 diabetes, but the levels of irisin are currently unknown. AIM: To characterize the levels of irisin in Type 1 diabetes and investigate a potential correlation with betatrophin.
METHODS: Irisin and betatrophin were measured by enzyme-linked immunosorbant assay (ELISA) in 45 individuals with Type 1 diabetes and in 25 healthy controls.
RESULTS: Irisin levels were increased in people with Type 1 diabetes, and especially in women. Negative correlations between irisin levels and age at onset of Type 1 diabetes and plasma triacylglycerol levels were observed. Interestingly, in women with Type 1 diabetes a negative correlation between irisin and insulin doses was also observed. When computing correlations for all study participants, a positive correlation between irisin and total betatrophin was observed, but not between irisin and full-length betatrophin.
CONCLUSION: We report on increased circulating levels of irisin in people with Type 1 diabetes, especially in women. For women with Type 1 diabetes, the levels of irisin correlated with lower insulin requirements. Further studies are clearly needed to determine the role of irisin in Type 1 diabetes.
© 2015 The Authors. Diabetic Medicine © 2015 Diabetes UK.

Entities:  

Mesh:

Substances:

Year:  2015        PMID: 25762196     DOI: 10.1111/dme.12731

Source DB:  PubMed          Journal:  Diabet Med        ISSN: 0742-3071            Impact factor:   4.359


  19 in total

Review 1.  Irisin in metabolic diseases.

Authors:  Stergios A Polyzos; Athanasios D Anastasilakis; Zoe A Efstathiadou; Polyzois Makras; Nikolaos Perakakis; Jannis Kountouras; Christos S Mantzoros
Journal:  Endocrine       Date:  2017-11-23       Impact factor: 3.633

2.  Irisin and Visfatin Predicts Severity of Diabetic Nephropathy.

Authors:  Ramalingam Mageswari; M G Sridhar; H Nandeesha; Sreejith Parameshwaran; K V Vinod
Journal:  Indian J Clin Biochem       Date:  2018-03-21

Review 3.  New insights into ANGPTL8 in modulating the development of cardio-metabolic disorder diseases.

Authors:  Xin Su; Guoming Zhang; Ye Cheng; Bin Wang
Journal:  Mol Biol Rep       Date:  2021-04-17       Impact factor: 2.316

4.  INFLUENCE OF GLYCEMIC CONTROL AND BODY COMPOSITION ON IRISIN LEVELS IN CHILDREN WITH TYPE 1 DIABETES MELLITUS.

Authors:  S E Beray; M E Atabek; Y Kücükkagnici; S Kurban; M B Selver; M S Iyisoy
Journal:  Acta Endocrinol (Buchar)       Date:  2022 Jan-Mar       Impact factor: 1.104

5.  Fibronectin type III domain-containing 5 in cardiovascular and metabolic diseases: a promising biomarker and therapeutic target.

Authors:  Xin Zhang; Can Hu; Hai-Ming Wu; Zhen-Guo Ma; Qi-Zhu Tang
Journal:  Acta Pharmacol Sin       Date:  2020-11-19       Impact factor: 7.169

6.  Increased Maternal and Cord Blood Betatrophin in Gestational Diabetes.

Authors:  Natalia Wawrusiewicz-Kurylonek; Beata Telejko; Mariusz Kuzmicki; Angelika Sobota; Danuta Lipinska; Justyna Pliszka; Beata Raczkowska; Pawel Kuc; Remigiusz Urban; Jacek Szamatowicz; Adam Kretowski; Piotr Laudanski; Maria Gorska
Journal:  PLoS One       Date:  2015-06-26       Impact factor: 3.240

7.  Circulating Betatrophin in Patients with Type 2 Diabetes: A Meta-Analysis.

Authors:  Sheyu Li; Dan Liu; Ling Li; Yun Li; Qianrui Li; Zhenmei An; Xin Sun; Haoming Tian
Journal:  J Diabetes Res       Date:  2015-12-01       Impact factor: 4.011

Review 8.  Mechanisms of altered bone remodeling in children with type 1 diabetes.

Authors:  Giacomina Brunetti; Gabriele D'Amato; Stefania De Santis; Maria Grano; Maria Felicia Faienza
Journal:  World J Diabetes       Date:  2021-07-15

9.  Novel myokine: irisin may be an independent predictor for subclinic atherosclerosis in Behçet's disease.

Authors:  Abdullah Icli; Erkan Cure; Medine Cumhur Cure; Ali Ugur Uslu; Sevket Balta; Sevket Arslan; Davut Sakiz; Adem Kucuk
Journal:  J Investig Med       Date:  2016-03-03       Impact factor: 2.895

10.  Irisin Inhibits Hepatic Cholesterol Synthesis via AMPK-SREBP2 Signaling.

Authors:  Hong Tang; Ruili Yu; Shiying Liu; Bahetiyaer Huwatibieke; Ziru Li; Weizhen Zhang
Journal:  EBioMedicine       Date:  2016-02-27       Impact factor: 8.143

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.